$ACMR

Cheav Sotheara sold $244K of ACMR

Cheav Sotheara (See remarks) sold 2,839 shares of ACM Research, Inc. (ACMR) at $85.77 ($0.24M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cheav Sotheara
Published Jun 6, 2026, 1:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 1:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ACMR
Neutral
medium confidence
Mentioned
$ACMR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACMRNeutralLow
01

Why it matters

The disclosure may slightly influence short-term sentiment, but it is not a fundamental catalyst given the stated 10b5-1 pre-arranged plan.

02

Market read

Traders may note the insider sale for sentiment/positioning, but the 10b5-1 designation suggests limited informational content.

03

What to watch

The article provides only one transaction size and does not indicate whether there were offsetting buys, broader insider activity trends, or changes in company guidance.

Relevance 6/10Novelty 3/10Timing: Filed 2026-06-05 after the sale executed 2026-06-04

Background

This is an SEC Form 4 insider transaction (officer/direct ownership) for ACM Research, Inc.

Company-level read

Ticker impact

$ACMRNeutralMedium confidence
Context

ACMR officer Cheav Sotheara sold 2,839 shares in an open-market transaction disclosed via SEC Form 4 on 2026-06-04.

Expected impact

Likely minimal near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure with a stated Rule 10b5-1 pre-arranged plan, reducing the likelihood it reflects new, nonpublic information.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than a view on ACMR fundamentals.

Key entities

  • ACM Research, Inc.

    Public company whose officer disclosed an open-market sale of common shares via SEC Form 4.

  • Cheav Sotheara

    Officer who executed and reported the sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACMRMed

AI Sovereignty Becomes a New National Security Battleground: Morgan Stanley Names SpaceX and 4 Other Beneficiary Stocks, with Upside Potential Topping 100% — BigGo Finance

Morgan Stanley identifies SpaceX, ACM Research, Amkor Technology, Alibaba, and KLA as key beneficiaries of the AI sovereignty trend. The bank assigns price targets with upside potential ranging from 21% to 105%, highlighting the strategic importance of AI infrastructure for national security and economic competitiveness.

$ACMRMed

ACM Research (NASDAQ: ACMR) unit’s orders surge past 100% with 42–48% margin outlook

ACM Research (Shanghai) reported a 105% year-over-year increase in new orders for the first half of 2026, with growth across electroplating, cleaning, and advanced packaging equipment. The company expects gross margins to remain between 42% and 48%. Significant orders include panel-level electroplating systems for delivery in 2026 and 2027. ACM Shanghai also highlighted rapid growth in mature-node semiconductor manufacturing and AI-related equipment demand.

$ACMRMedAI 9/10

ACM Research (ACMR) Q2 2026 Earnings Call Transcript

ACM Research (ACMR) reported Q2 2026 revenue of $292.9M, up 36% year over year, with non-GAAP diluted EPS of $0.61. Non-GAAP gross margin was 46.0%. The company raised 2026 revenue guidance to $1.125B-$1.175B and said first-half orders rose 105%. Net cash was $1.0B.